Drug Trial Radar · NCT04706923
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Aug 16, 2021
Primary completion
May 15, 2025
Study completion May 15, 2025
Sponsor
- Lead sponsor
- SymBio PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Conditions
- Adenovirus Infections
- Cytomegalovirus Infection
Interventions
BCVDrug
Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments.Time frame: From initiation of BCV administration up to 19 weeks
- Antiviral EffectsTime frame: From initiation of BCV administration up to 9 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
San Francisco, California
Research Site
Chicago, Illinois
University of Nebraska Medical Center
Omaha, Nebraska
Research Site
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Research Site
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
MD Anderson Cancer Center
Houston, Texas
Research Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.